LY 3050258

Drug Profile

LY 3050258

Alternative Names: LY-3050258

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 22 Apr 2014 Eli Lilly plans a phase I trial for Healthy volunteers in USA (NCT02121834)
  • 01 Dec 2013 Eli Lilly completes a phase I trial in Healthy volunteers in USA (NCT01929707)
  • 21 Nov 2013 Eli Lilly completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01929707)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top